Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients
Status:
Completed
Trial end date:
2017-01-04
Target enrollment:
Participant gender:
Summary
To determine the safety of administering anakinra plus the physician's chemotherapy choice
(TPC) of nab paclitaxel, capecitabine, eribulin, or vinorelbine in patients with metastatic
breast cancer (MBC), as well as determining blood immune cell transcriptional signatures in
patients who undergo IL-1 receptor blockade.
Phase:
Phase 1
Details
Lead Sponsor:
Baylor Research Institute
Treatments:
Albumin-Bound Paclitaxel Capecitabine Interleukin 1 Receptor Antagonist Protein Paclitaxel Vinorelbine